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2 
Abstract 22 
Due to the limited efficiency of conventional biological treatment, innovative solutions are being 23 
explored to improve the removal of trace organic chemicals in wastewater. Controlling biomass 24 
exposure to growth substrate represents an appealing option for process optimization, as 25 
substrate availability likely impacts microbial activity, hence organic trace chemical removal. 26 
This study investigated the elimination of pharmaceuticals in pre-denitrifying moving bed 27 
biofilm reactors (MBBRs), where biofilm exposure to different organic substrate loading and 28 
composition was controlled by reactor staging. A three-stage MBBR and a single-stage reference 29 
MBBR (with the same operating volume and filling ratio) were operated under continuous-flow 30 
conditions (18 months). Two sets of batch experiments (day 100 and 471) were performed to 31 
quantify and compare pharmaceutical removal and denitrification kinetics in the different 32 
MBBRs. Experimental results revealed the possible influence of retransformation (e.g., from 33 
conjugated metabolites) and enantioselectivity on the removal of selected pharmaceuticals. In 34 
the second set of experiments, specific trends in denitrification and biotransformation kinetics 35 
were observed, with highest and lowest rates/rate constants in the first (S1) and the last (S3) 36 
staged sub-reactors, respectively. These observations were confirmed by removal efficiency data 37 
obtained during continuous-flow operation, with limited removal (<10%) of recalcitrant 38 
pharmaceuticals and highest removal in S1 within the three-stage MBBR. Notably, 39 
biotransformation rate constants obtained for non-recalcitrant pharmaceuticals correlated with 40 
mean specific denitrification rates, maximum specific growth rates and observed growth yield 41 
values. Overall, these findings suggest that: (i) the long-term exposure to tiered substrate 42 
accessibility in the three-stage configuration shaped the denitrification and biotransformation 43 
capacity of biofilms, with significant reduction under substrate limitation; (ii) biotransformation 44 
of pharmaceuticals may have occurred as a result of cometabolism by heterotrophic denitrifying 45 
3 
bacteria. 46 
 47 
Keywords: Moving bed biofilm reactors, pharmaceutical biodegradation, heterotrophic 48 
denitrification, reactor staging, organic substrate  49 
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1. Introduction  50 
Elimination of pharmaceuticals and other trace organic chemicals represents a major challenge 51 
in conventional wastewater treatment systems. Innovative solutions, e.g., novel treatment 52 
technologies or process configurations, have been explored to improve the removal efficiency 53 
in biological wastewater treatment facilities.  54 
Among the plethora of evaluated options, staging of biological reactors (defined as the 55 
subdivision into two or more completely mixed sub-reactors in series) has been proposed to 56 
optimize pollutant removal processes based on reaction kinetic principles (Scuras et al., 2001; 57 
Joss et al., 2006; Grady et al., 2011). Staging of pre-denitrifying reactors (Plósz, 2007; Plósz et 58 
al., 2010a) was accordingly hypothesized to enhance denitrification as compared to single-stage 59 
configurations. In staged systems with prolonged physical biomass retention (i.e. as biofilms), 60 
microbial adaptation to specific substrate availability conditions can be induced in each sub-61 
stage. As to pre-denitrifying systems, shaping of microbial activity and community is determined 62 
by the availability and the quality (e.g., in terms of degradability) of electron donating organic 63 
substrate. Nevertheless, it is unknown how reactor staging would impact the removal (via 64 
biotransformation) of trace organic chemicals. Although it has been hypothesized that the 65 
degradation of more recalcitrant organics (such as xenobiotics) would occur in substrate-limited 66 
staged denitrifying reactors (Plósz et al., 2010a)—as also observed under aerobic conditions 67 
(Escolá Casas et al., 2015)—no evidence is currently available. 68 
Recently, moving bed biofilm reactors (MBBRs) have been considered as an option to improve 69 
the removal of pharmaceuticals. In MBBRs, biomass grows on suspended plastic carriers 70 
(Ødegaard et al., 1994), with expected increase of biomass residence time compared to activated 71 
sludge systems. Enhanced biotransformation was accordingly observed in nitrifying MBBRs for 72 
a number of pharmaceuticals (Falås et al., 2012, 2013; Torresi et al., 2016). As the wide majority 73 
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of studies have focused on aerobic conditions (in line with overall literature on biodegradation 74 
of xenobiotics; Ghattas et al., 2017), little is known about denitrifying MBBRs, with detailed 75 
information only recently obtained for post-denitrifying systems (Torresi et al., 2017). 76 
In this study, we investigated the elimination of pharmaceuticals in single-stage and three-stage 77 
MBBR configurations for pre-denitrification of municipal wastewater. We assessed the effect of 78 
organic substrate availability on pharmaceutical degradation and ensured prolonged biomass 79 
exposure (via immobilization on carriers) to specific substrate availability conditions. During 80 
long-term continuous operation of the two systems, batch experiments were performed at two 81 
distinct time points to assess kinetics of heterotrophic denitrification and pharmaceutical 82 
removal in each MBBR. Indigenous pharmaceutical concentrations in wastewater media were 83 
used in the study, given the potentially significant influence of spiking on transformation kinetics 84 
and pathways (Collado et al., 2012; Jewell et al., 2016) as well as the possibility of 85 
retransformation from conjugated metabolites and structural analogues (Polesel et al., 2016). 86 
The main objectives of our investigation were: (i) to assess and compare kinetics of 87 
denitrification (primary metabolic function) and pharmaceutical biotransformation (secondary 88 
metabolic function) in different MBBR systems; (ii) to assess the influence of biofilm exposure 89 
to different organic substrate loading and complexity, resulting from MBBR staging, on its 90 
capability of reducing nitrate and nitrite and biotransforming selected pharmaceuticals; and (iii) 91 
to eventually investigate the association between primary and secondary metabolic functions. 92 
Specifically, two alternative hypotheses were tested: 93 
 Strongly limiting organic substrate availability (in the downstream reactor stages) induces an 94 
improvement of pharmaceutical biotransformation kinetics, due to the possible improvement 95 
in utilizing more recalcitrant chemicals (e.g. of pharmaceuticals) as secondary/secondary-96 
cometabolic substrates;   97 
6 
 Non-limiting organic substrate availability (occurring in the upstream reactor stages) 98 
positively influences pharmaceutical biotransformation kinetics by more effectively fueling 99 
denitrifying activity. 100 
 101 
2. Materials and methods 102 
2.1. System description and operation 103 
Two laboratory scale pre-denitrifying MBBR configurations with K1 carriers (AnoxKaldnes, 104 
Lund, Sweden; specific surface area = 500 m2 m-3) were operated in parallel under continuous-105 
flow conditions for 1.5 years (Fig. 1). The two configurations were operated under identical 106 
conditions, i.e. influent flow rate, hydraulic residence time, influent medium characteristics, to 107 
allow for a comparative assessment of system performance.  108 
The single-stage configuration included a single bioreactor (U) with operating volume of 6 L. 109 
The three-stage configuration was designed according to principles presented by Plósz (2007) 110 
and included three reactors in series (named S1, S2, S3) with a total operating volume of 6 L 111 
(1.5 L for S1 and S2 and 3 L for S3). To limit O2 penetration, reactors were continuously sparged 112 
with N2 gas (≥ 99.996%, Aga A/S, Copenhagen, Denmark) and provided with polystyrene lids 113 
and rubber top sealing, having a small opening that allowed for sparging gas to escape. These 114 
solutions allowed establishing DO concentrations lower than 0.05 mg L-1 in all MBBRs for the 115 
duration of the experiment. Sparging of N2 gas was also used for mechanical mixing of K1 116 
carriers.  117 
MBBR carriers with attached biofilm used for reactor seeding were collected from the post-118 
denitrification zone of Sjölunda WWTP (Malmö, Sweden). The post-denitrifying train of 119 
Sjölunda WWTP consists of two tanks in series, whereby dosage of external carbon source 120 
(methanol) takes place in the first tank of the treatment train while MBBR carriers (and attached 121 
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biofilms) were collected from the second tank. A filling ratio of 33% was selected for all reactors. 122 
All MBBRs were operated at ambient temperature (?). 123 
The two configurations were continuously fed with primary wastewater effluent (Mølleåværket 124 
WWTP, Lundtofte, Denmark) at an influent flow rate of 15 L d-1 for each system. Pre-clarified 125 
wastewater was collected semi-weekly, stored in a 200 L stirred cooling tank (< 4°C) and fed to 126 
the MBBR reactors using a peristaltic pump (Ole Dich, Hvidovre, Denmark). Nitrate was 127 
supplied to both MBBR systems from a 10 g L-1 dosing solution of KNO3 (≥ 99.9%, Merck 128 
Millipore, Darmstadt, Germany), fed at a flow rate of 1.2 L d-1 using another peristaltic pump 129 
(Ole Dich, Hvidovre, Denmark). The resulting influent nitrate concentration (103 mgN L-1) 130 
ensured that there was a residual nitrate in the treated effluent, thereby allowing for 131 
denitrification to occur in all of the reactors at all times, i.e. that MBBR biofilm could 132 
permanently be subject to anoxic conditions. As in full-scale pre-denitrifying systems, the 133 
indigenous COD content of pre-clarified wastewater was the only electron donor available for 134 
denitrification, i.e. no extra carbon source was supplied. Furthermore, during the entire operation 135 
period both systems received only indigenous pharmaceutical concentrations present in the 136 
feeding medium. 137 
The two MBBR systems were monitored during continuous-flow operation for approximately 138 
1.5 months before and/or after batch experiments (see Chapter 2.2). System performance in terms 139 
of heterotrophic denitrification and pharmaceutical removal was assessed by monitoring influent 140 
and effluent concentrations of COD, NO3-N, NO2-N and pharmaceuticals (see section S4, Table 141 
S5). Characterization of organic substrates in the influent wastewater was carried out according 142 
to Roeleveld and van Loosdrecht (2002). 143 
< Figure 1 > 144 
 145 
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2.2. Batch experiments 146 
2.2.1. Biotic 147 
Batch experiments were performed to assess biokinetics of heterotrophic denitrification and 148 
pharmaceuticals elimination in the four MBBRs (U, S1, S2, S3). Two sets of batch experiments 149 
were performed during 1.5 year of continuous operation: Batch 1 (day 100) and Batch 2 (day 150 
471). In both cases, the continuous MBBR systems were disconnected and experiments were 151 
performed with carriers from U, S1, S2 and S3 separately at the same boundary and initial 152 
conditions (feeding medium characteristics, filling ratio, reactor operation).  153 
Similarly to continuous-flow operation, pre-clarified wastewater from Mølleåværket WWTP 154 
was used as feeding medium in batch experiments. The medium was supplemented with KNO3, 155 
resulting in an initial NO3-N concentration of 100–104 mgN L-1. DO concentration was 156 
minimized through continuous sparging of N2 gas. Temperature and pH were continuously 157 
monitored (SenTix® 980, WTW, Weilheim, Germany). Manual pH adjustment with 1 M HCl 158 
was performed at the beginning and through the experiment to prevent microbial activity 159 
inhibition. Experiments were performed at ambient temperature. Spiking of reference 160 
pharmaceuticals was not used, and only the indigenous chemicals occurring in pre-clarified 161 
wastewater were quantified. Aqueous samples for the analysis of pharmaceuticals and 162 
conventional pollutants were withdrawn from MBBRs and concurrently a fixed number of 163 
carriers were removed to maintain a constant filling ratio. 164 
The duration of Batch 1 was 24 h, with MBBR filling adjusted to 20%. The temperature during 165 
batch experiments was (mean and standard deviation, 5 min frequency): 20.3 ± 0.9°C for S1, 166 
20.2 ± 1.3°C for S2, 20.3 ± 1.0°C for S3, 20.3 ± 0.9°C for U. In Batch 2, a filling ratio of 10% 167 
was used and the experiment duration was extended to 49 h. The temperature during batch 168 
experiments was (mean and standard deviation, 10 min frequency): 16.7 ± 0.5°C for S1, 17.4 ± 169 
9 
0.5°C for S2, 16.8 ± 0.4°C for S3, 17.0 ± 0.5°C for U. 170 
 171 
2.2.2. Control experiments 172 
A reference batch experiment (abiotic control experiment) was additionally performed to assess 173 
abiotic degradation of pharmaceuticals, based on the methodology proposed by Falås et al. 174 
(2013). The experiment was conducted in a glass container with 200 mL pre-filtered (GF filter, 175 
0.6 µm pore size, Advantec, Knebel, Denmark) pre-clarified wastewater (Mølleåværket WWTP, 176 
Lundtofte, Denmark). Reactor mixing was ensured by N2 gas sparging. The experiment was 177 
conducted in the absence (first 2 h) and in the presence of plastic carriers without biofilm (last 178 
2 h), with an overall duration of 4 h. Aqueous samples were withdrawn at t=0, 2 and 4 h. An 179 
evaporation control experiment was additionally carried out in parallel to assess the evaporation 180 
of filtered wastewater due to N2 gas sparging. Two glass containers (working volume = 200 mL) 181 
were operated in parallel and under the same conditions of the reference control experiment. 182 
Residual liquid volume was measured in the two reactors after 2 h and 4 h, respectively.   183 
 184 
2.3. Analytical methods 185 
Samples for the analysis of conventional pollutants were collected and analysed for total and 186 
soluble COD, NO3-N and NO2-N. Non-filtered and filtered samples (0.45 µm GF filters; 187 
Sartorius, Göttingen, Germany) were stored in plastic vials at ≤ 4°C until analysis (for non-188 
filtered samples, within 24 h from collection). COD concentrations were quantified using Hach-189 
Lange colorimetric kits (LCK314, LCK514) and Hach-Lange DR 2800 spectrophotometer. NO3-190 
N and NO2-N concentrations were quantified with Merck colorimetric kits and subsequent 191 
spectrophotometric quantification (batch 1) or with a Bran Luebbe® Auto Analyzer 3 digital 192 
colorimeter (batch 2). 193 
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The concentration of attached biomass was determined from the weight difference of multiple 194 
(≥ 5) dried carriers (105°C for >1 h) before and after biofilm removal, as described in Falås et 195 
al. (2012). Attached biofilm was removed from plastic carriers using H2SO4 (4M) and thorough 196 
brushing. The resulting biomass concentration was expressed in terms of total attached solids 197 
(gTAS L-1). Conversion factors TSS/TAS and VSS/TAS for biofilm in each MBBR were 198 
determined via parallel measurements of TAS, TSS and VSS content.  Biofilm from five carriers 199 
for each MBBR was detached and resuspended in 50 mL tap water. Four replicate measurements 200 
were performed, with overall biofilm detachment from 20 carriers per MBBR. TAS (in analogy 201 
with total solids), TSS and VSS concentrations of the suspension were measured according to 202 
APHA standard methods (Clesceri et al., 1998). Determination of TSS/TAS ratio allowed 203 
converting attached biomass concentration to gTSS L-1. The overall TSS concentration in each 204 
MBBR was eventually determined by accounting for TSS in bulk aqueous phase (separate 205 
measurement according to APHA standard methods).  206 
Samples for pharmaceutical analysis were collected and prepared according to the procedure 207 
described by Escolá Casas et al. (2015). Briefly, 4 ml wastewater samples were collected and 208 
stored in glass vials (Chromacol 22 mL, Mikrolab, Aarhus, Denmark). 1.4 ml pure methanol (≥ 209 
99.9%, Merck Millipore) was added to inhibit biological activity during the storage period. 210 
Prepared samples were then preserved at -20°C. Subsequently, 1.5 mL was of each sample were 211 
transferred to an HPLC vial and were centrifuged (6000 rpm, 10 minutes) to separate residual 212 
solids. 900 µL of the supernatant were transferred to a new vial, to which 100 µL of internal 213 
standard solution were added using a glass syringe. Samples were analyzed using HPLC-MS/MS 214 
with an injected volume of 100 µL. Twenty-three active pharmaceutical substances, typically 215 
present in wastewater influents, were targeted. A complete list of these substances is given in 216 
the Supporting Information (section S4) and elsewhere (Escolá Casas et al., 2015). 217 
11 
Specifications of the HPLC-MS/MS analytical device and of the internal standard solution can 218 
be found in Escolá Casas et al. (2015).  219 
 220 
2.4. Anoxic respirometry 221 
In batch 1 and 2, heterotrophic denitrification was assessed by measuring NO3-N and NO2-N 222 
(mgN L-1) concentrations in different MBBRs. NO2-N concentration was measured due to the 223 
possibility of nitrite accumulation, as shown in previous experiments (Ubay Çokgör et al., 1998; 224 
Kujawa and Klapwijk, 1999; Ekama and Wentzel, 1999), thus being accounted for when 225 
characterizing denitrification kinetics. Based on measured NO3-N and NO2-N concentrations, 226 
anoxic respirograms were derived for each batch experiment as NOX utilization curves, where 227 
NOX-N concentration (mgN L-1) was calculated according to Eq. 1 (Ubay Çokgör et al., 1998): 228 
NNONNONNOX  23 6.0                (1) 229 
In this equation, the coefficient 0.6 denotes the relative amount of electrons required to reduce 230 
NO2 to N2 (3 e-) compared to the reduction of NO3 to N2 (5 e-). It is anticipated that two distinct 231 
NOX utilization rates could be distinguished during batch experiments (Fig. S5). Fast slow 232 
specific denitrification rates (k1 and k2, respectively; mgN gTSS-1 d-1) were accordingly derived 233 
in each MBBR through linear regression of NOX concentrations and normalization to biomass 234 
concentration (as gTSS L-1). In order to provide for a unique kinetic descriptor of denitrification, 235 
the mean specific denitrification rate NOXk (mgN gTSS-1 d-1) was calculated (Eq. 2): 236 
2
21 kkk NOX
  (2) 237 
Surface-normalized mean denitrification rates ( NOXr , r1 and r2, gN m-2 d-1) were also derived 238 
for each MBBR. The rationale for the interpretation of anoxic respirometric data, as well as the 239 
definition of denitrification rates, is described in detailed in the Supporting Information (section 240 
12 
S3). 241 
 242 
2.5. Modelling pharmaceutical removal kinetics 243 
Based on observations on pharmaceutical removal in Batch 1 and 2, model structures were 244 
identified using the Activated Sludge Model framework for Xenobiotics (ASM-X) (Plósz et al., 245 
2010b, 2012), including recent extensions presented by Torresi et al. (2017). A summary of 246 
identified model structures is shown in Table 1. 247 
In the simplest model structure, pseudo-first-order degradation kinetics was used to describe 248 
aqueous concentration decrease (Eq. 3)  249 
TSSLI
TSSd
bioLI XC
XK
k
dt
dC
)1( 
                 (3) 250 
where CLI denotes the aqueous pharmaceutical concentration (ng L-1), kbio the biotransformation 251 
rate constant (L gTSS-1 d-1) and XTSS the biomass concentration in MBBRs (gTSS L-1). A 252 
correction factor for sorption was considered, where Kd (L g-1) denotes the sorption coefficient, 253 
assuming instantaneous equilibrium between aqueous and sorbed concentrations (Joss et al., 254 
2006). Constant XTSS was assumed, considering negligible biomass growth during batch 255 
experiments. The effect of diffusion into biofilm on the removal of pharmaceuticals from bulk 256 
aqueous phase was lumped in the biotransformation rate constants (Falås et al., 2012, 2013; 257 
Escolá Casas et al., 2015; Torresi et al., 2016, 2017). 258 
The transformation of human metabolites and other fractions (Polesel et al., 2016) may lead to 259 
the formation of parent compounds and can be additionally described using pseudo-first-order 260 
kinetics (Eq. 4): 261 
TSSCJdec
CJ XCk
dt
dC                     (4) 262 
where the state variable CCJ denotes the retransformable pharmaceutical fractions (e.g., 263 
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conjugated metabolites) and kdec (L gTSS-1 d-1) denotes the retransformation rate constant. 264 
Negligible sorption was considered for the fraction CCJ due to its potentially high hydrophilicity 265 
(Göbel et al., 2005; Plósz et al., 2010b). Simultaneous parent compound formation and 266 
biotransformation were thus described using Eq. 5: 267 
TSSCJdecTSSLI
TSSd
bioLI XCkXC
XK
k
dt
dC 


)1(
           (5) 268 
or, in case of only one major conjugated metabolite, using Eq. 6: 269 
TSSCJdec
CJ
LI
TSSLI
TSSd
bioLI XCk
M
MXC
XK
k
dt
dC 


)1(
         (6) 270 
where MLI and MCJ (g mol-1) denote the molecular mass of the parent compound and the 271 
conjugate, respectively, and their ratio denotes the stoichiometry coefficient of retransformation 272 
(Plósz et al., 2013; Torresi et al., 2017). 273 
 274 
2.6. Parameter estimation 275 
Estimation of transformation rate constants (kbio, kdec) required the initial assumption of Kd. 276 
Values measured in activated sludge—where available under denitrifying conditions—were 277 
collected from published literature (Ternes et al., 2004; Göbel et al., 2005; Maurer et al., 2007; 278 
Radjenovic et al., 2009; Wick et al., 2009; Plósz et al., 2010b; Hörsing et al., 2011; Plósz et al., 279 
2012). In absence of published Kd values, negligible sorption was assumed. Table S6 summarizes 280 
Kd values for detected pharmaceuticals.  281 
When parent compound formation was observed in the absence of CCJ measurements, the initial 282 
concentration CCJ,0 (ng L-1) was defined by assuming the same initial ratio nLI,CJ (Eq. 7) in all 283 
simultaneous batch experiments:    284 
0,
0,
,
CJ
LI
CJLI C
C
n                        (7) 285 
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where CLI,0 denotes the initial parent compound concentration (ng L-1). In this case, calibration 286 
of Eq. 5 was performed for all experiments simultaneous, also with the estimation of nLI,CJ. 287 
In all cases, model calibration against experimental data in Batch 1 and 2 was performed using 288 
the secant method embedded in Aquasim 2.1d (Reichert, 1998). Surface-normalized 289 
transformation rate constants (L-1 m-2 d-1) were eventually calculated from estimated kbio and kdec 290 
values.  291 
< Table 1 > 292 
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3. Results and discussion 293 
3.1. Heterotrophic denitrification 294 
3.1.1. Monitoring during continuous-flow operation 295 
Due to considerable fluctuations in the quality of the wastewater influent, dynamics in NOX 296 
removal were shown (Table S1, Fig. S2). Variability was observed in terms of influent 297 
concentrations of total COD (207 ± 57.3 mgCOD L-1), soluble COD (84 ± 25.7 mgCOD L-1), 298 
biodegradable COD (136 ± 41.6 mgCOD L-1), readily biodegradable COD (SS, 60.5 ± 25.0 299 
mgCOD L-1) and hydrolizable COD (XS, 75.4 ± 36.5 mgCOD L-1). NOX removal per influent 300 
total COD was calculated, being 0.15–0.18 mgNOX-N mgCOD-1 for three-stage MBBR and 301 
0.12–0.16 mgNOX-N mgCOD-1 for single-stage MBBR (Table S2). NO2-N accumulation in the 302 
MBBR reactors was accounted for when calculating NOX removal as shown in Eq. 1. 303 
Surface-normalized NOX removal rates exhibited a significant decrease after 400 days of 304 
operation (Table S2). This may be attributed to the reduced average influent loading of organic 305 
substrate (before day 100: 3.95 ± 0.87 gCOD d-1; after day 400: 2.66 ± 0.41 gCOD d-1; here 306 
expressed as total COD).   307 
Reactor staging effectively determined a declining gradient of influent substrate loading from 308 
S1 to S3 (Table S3). Temporal trends of attached biomass concentration (gTAS L-1) in each 309 
MBBR indicated significant growth as compared to the inoculum (Fig. S1). Faster growth was 310 
observed in S1, with stable biomass concentration reached after approximately 80 days, as 311 
compared to the other reactors (> 100 d). Towards the end of the operation period, the highest 312 
biomass concentration was found in S2 (5.2 gTAS L-1) and comparable concentrations were 313 
found in the other MBBRs (3.9–4.2 gTAS L-1). 314 
 315 
3.1.2. Batch experiments (1 and 2) 316 
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Measured concentration profiles of NO3-N, NO2-N, total and soluble COD are presented in Fig. 317 
S3 (Batch 1) and Fig. S4 (Batch 2). In all experiments, NO2-N accumulation was observed, being 318 
more prominent in batch 2 (up to 10 mgN L-1 in S3). The residual soluble COD concentration 319 
was found comparable (52.7 ± 3.2 mgCOD L-1 in batch 1; 53.9 ± 6.9 in batch 2), representing 320 
the inert organic matter not utilizable as electron donor.  321 
In batch 1, depletion of organic substrate in the wastewater medium (based on soluble COD 322 
measurements) was reached after 0.2–0.4 d, typically coinciding (except for S3) with a change 323 
in NOX reduction rate (Fig. S5a). As to NOX reduction kinetics, no trend was shown for NOXk  in 324 
the three staged MBBRs (Table S4). 325 
A number of peculiar observations were made during batch 2, which will be thus discussed more 326 
in detail. Fig. 2 presents measured concentration profiles of NOX (a) and total COD (b) in the 327 
different MBBRs during batch 2. Experimental data revealed significantly different 328 
denitrification capacity and kinetics in MBBRs. Notably, initial lag phases in NOX reduction 329 
were found in S2, U (1.5 h) and S3 (3 h) (Fig. 2a), possibly resulting from the prior limited 330 
exposure of biofilm in these MBBRs to readily biodegradable organic substrate. As to S2 and 331 
S3, this indicates that the three-staged reactor design achieved exposing biofilm to limiting and 332 
highly limiting organic substrate, respectively (Plósz, 2007). Furthermore, NOX reduction during 333 
continuous-flow operation predominantly relied on hydrolysis products also in the single-stage 334 
system U. 335 
NOX reduction rates were determined by neglecting the initial lag phase (Fig. S5). Calculated 336 
NOXk  values were 48.2 mgN gTSS-1 for S1, 18.9 mgN gTSS-1 for S2, 12.4 mgN gTSS-1 for S3 337 
and 20.3 mgN gTSS-1 for U. When considering the three-stage system, NOXk (and the surface-338 
normalized rate NOXr ) declined from S1 to S3, indicating that different organic substrate loading 339 
and availability influenced both the capacity and the kinetics of NOX reduction in MBBR 340 
17 
biofilm. A substantial decrease of NOXk  and NOXr  was observed in batch 2 as compared to batch 341 
1 (Table S4), being more pronounced in S2, S3 and U. Not unexpectedly, both biomass- and 342 
surface-normalized rates were significantly lower than in post-denitrifying MBBRs, where only 343 
easily degradable external organic substrate is used as electron donor (Torresi et al., 2017). 344 
Different levels of NOX reduction were achieved in all MBBRs with comparable total COD 345 
removal (ΔCOD=257–275 mgCOD L-1 over 48 h) and utilization kinetics (Fig. 2b). Accordingly, 346 
COD storage may have occurred in S2, S3 and U due to biofilm exposure to feast substrate 347 
availability conditions following prolonged famine during continuous-flow operation, as 348 
previously shown for denitrifying bacteria (Beun et al., 2000). The microbial growth yield, YH 349 
(mgCOD mgCOD-1) was thus calculated based on measured NOX and COD concentrations. The 350 
calculation of YH (Eq. 8) was based on NOX and COD utilization during fast denitrification 351 
(without considering the initial lag phase in S2, S3 and U), thus better approximating the true 352 
yield:   353 
COD
NOY XH 
 86.21                     (8) 354 
where 2.86 (mgCOD mgN-1) denotes the COD equivalents of NOX-N (with the reduced number 355 
of COD equivalents of NO2-N accounted for in Eq. 1). ΔNOX (mgN L-1) and ΔCOD (mgCOD L-356 
1) denote the NOX and total COD utilized during fast denitrification in batch 2, respectively, and 357 
were quantified using an intercept-based method. Further details on the method (and examples 358 
for S1 and S3) are provided in Fig. S6. A value of 0.53 was calculated for YH in S1, in agreement 359 
with typical values for denitrification (Ubay Çokgör et al., 1998). Higher YH values were instead 360 
found for S2, S3 and U (0.61, 0.77 and 0.67, respectively), further suggesting the occurrence of 361 
substrate storage in these MBBRs (Muller et al., 2003).  362 
Furthermore, maximum specific growth rates (µmax) in each MBBR were derived from the fast 363 
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denitrification rate k1 (using the calculated yield YH), according to the method proposed by 364 
Ekama and Wentzel (2008). Estimated µmax values were 0.22, 0.12, 0.16 and 0.17 d-1 in S1, S2, 365 
S3 and U, respectively. These values were lower than that estimated for nitrate and nitrite 366 
reduction in activated sludge using single organic substrate (Pan et al., 2015), but were in 367 
agreement with estimations for ethanol-fed post-denitrifying MBBR (Torresi et al., 2017). It 368 
should be noted that the presented values may include (for S2, U and especially S3) both the 369 
rates of growth and simultaneous substrate storage.  370 
< Figure 2 > 371 
 372 
3.2. Removal of pharmaceuticals 373 
Based on measured concentrations during continuous-flow operation and in batch 1 and 2, it was 374 
possible to characterize the removal of a number of substances, namely: (i) the beta-blockers 375 
atenolol (ATN) and metoprolol (MET); (ii) the sulfonamide antibiotics sulfamethoxazole 376 
(SMX), sulfamethizole (SMZ), sulfadiazine (SDZ) and its conjugated metabolite acetyl-377 
sulfadiazine (AcSDZ), and the combination product trimethoprim (TMP); the macrolides 378 
antibiotic erythromycin (ERY); (iv) the anti-inflammatory pharmaceuticals diclofenac (DCF) 379 
and ibuprofen (IBU); (v) the X-ray contrast medium iohexol (IOH); (vi) and the anti-depressants 380 
citalopram (CIT) and venlafaxine (VFX). Since only indigenous concentrations were considered 381 
(i.e., no spiking of reference substances was performed), this is only a sub-sample of the initially 382 
targeted pharmaceuticals. Further details on the quantified chemicals can be found in Table S5. 383 
In the following sections, results will be thus presented and discussed for the listed substances. 384 
 385 
3.2.1. Abiotic transformation during control experiments 386 
Negligible (≤15%) or no removal was observed in the abiotic control experiment (Fig. S11), in 387 
agreement with previous studies (Falås et al., 2012, 2013; Torresi et al., 2016). For almost all 388 
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substances (ATN, DCF, IOH, IBU, MET, SMZ, SDZ, AcSDZ, TMP, VFX), an increase of 389 
aqueous concentration (on average +16%) was observed and could be attributed to wastewater 390 
evaporation during the evaporation control experiment (Fig. S12). 391 
 392 
3.2.2. Biotransformation kinetics (batch 1 and 2) 393 
Measured pharmaceutical concentrations in batch 1 and 2 exhibited a number of typical patterns 394 
(Fig. 3), which could be interpreted in most cases using Eq. 3–6. A complete overview of 395 
measured concentration profiles in both batch experiments is given in Fig. S7–8. Differently 396 
from NOX reduction, no lag phase in the removal of pharmaceuticals was shown in batch 2.  397 
Several pharmaceuticals (TMP in batch 1; ATN, ERY, IBU, IOH, SMZ, TMP and VFX in batch 398 
2) exhibited elimination as in Figure 3a, following pseudo-first-order kinetics (Eq. 3) that were 399 
described by kbio. 400 
Initial increase of aqueous concentration was observed for SMX, SDZ, DCF and MET (Fig. 3b–401 
c). Retransformation of these pharmaceuticals can occur from conjugated metabolites, structural 402 
analogues and/or parent pharmaceuticals (Polesel et al., 2016) and was considered to explain 403 
these profiles. SMX is excreted in the form of parent and two major conjugated metabolites, N4-404 
acetyl-SMX and SMX-N1-glucuronide (Vree et al., 1995; van der Ven et al., 1995), which were 405 
shown to transform back to parent SMX in laboratory- and full-scale studies (Göbel et al., 2005; 406 
Plósz et al., 2010; Radke et al., 2009; Stadler et al., 2015). SDZ is known to have only one major 407 
conjugated metabolite, AcSDZ (Vree and Hekster, 1987), which could also be quantified during 408 
batch 1 (Fig S6e–f). Eq. 4 and 6 were thus simultaneously calibrated to AcSDZ and SDZ 409 
measurements, respectively, allowing for the estimation of kdec and kbio. DCF is also excreted as 410 
sulfate and glucuronide conjugates (Stierlin and Faigle, 1979), and its formation was reported in 411 
laboratory experiments (Lee et al., 2012) and in full-scale WWTPs (Zhang et al., 2008; Plósz et 412 
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al., 2012; Vieno and Sillanpää, 2014). As to MET, excretion as conjugated metabolite is 413 
negligible (Escher et al., 2006). Formation of MET was still observed in pilot- and full-scale 414 
WWTPs (Bendz et al., 2005; Radjenovic et al., 2009; Wick et al., 2009; de Graaff et al., 2011; 415 
Jelic et al., 2011). Although these observations have been attributed to sampling and/or 416 
analytical uncertainties (Alder et al., 2010), formation from a structurally analogue chemical 417 
may not be excluded (in particular under denitrifying conditions).   418 
In two cases (ATN in batch 1, CIT in batch 2), Eq. 3 did not adequately describe batch removal 419 
kinetics. Notably, ATN and CIT are chiral and both enantiomers are present in wastewater 420 
(Kasprzyk-Hordern and Baker, 2011; Evans et al., 2015). Similar observations were made for 421 
another chiral pharmaceutical, propranolol (Escolá Casas et al., 2015). In analogy with the latter 422 
study, enantioselective biotransformation was hypothesized to determine the two-rate profile 423 
observed in batch experiments in all four MBBRs (Fig. 3d). Pseudo-first-order transformation 424 
kinetics was assumed for the two enantiomers, being described by rate constants kbio,1 and kbio,2 425 
(L gTSS-1 d-1). Biotransformation of ATN and CIT was thus described according to Eq. 9 (Table 426 
1): 427 
TSSENbioENbio
TSSd
LI XCkCk
XKdt
dC )(
)1(
1
2,2,1,1, 
              (9) 428 
where CEN,1 and CEN,2 (ng L-1) denote the aqueous concentrations of the two enantiomers, 429 
respectively, and CLI (ng L-1) is the sum of CEN,1 and CEN,2. Initial conditions for CEN,1 and CEN,2 430 
were set by considering in all simultaneous batch experiments the same initial enantiomeric 431 
fraction EF (Ribeiro et al., 2013; Eq. 10): 432 
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              (10) 433 
Through calibration of Eq. 9 to all batch experiments simultaneously, the parameters kbio,1, kbio,2 434 
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and EF could be estimated. The enantioselective biotransformation model (Fig. 3d; Fig. S7a and 435 
S8k) was shown to significantly improve the prediction of measured concentrations for ATN 436 
and CIT (R2 = 0.95–0.99) as compared to a simple first-order equation (Fig. S9).  Nevertheless, 437 
this hypothesis requires further confirmation, with identification and quantification of the two 438 
enantiomers of ATN and CIT.  439 
< Figure 3 > 440 
Estimated rate constants (kbio, kdec, kbio,1, kbio,2) in batch 1 and 2 are presented in Fig. 4 (a and b, 441 
respectively). In Table 2, rate constants from this study are compared with literature values for 442 
denitrifying activated sludge (DNAS), nitrifying MBBR (NMBBR) and post-denitrifying MBBR 443 
(DNMBBR).  444 
In batch 1, the highest rate constant values were estimated either for S1 or U (Fig. 4a), while no 445 
overall trend could be identified when considering staged MBBRs only. All the quantifiable 446 
pharmaceuticals exhibited comparably high transformation and formation kinetics with the 447 
exception of DCF. Rapid retransformation was shown, with kdec typically higher than 1 L g-1 448 
TSS-1 and in agreement with previously observed formation (e.g., via deconjugation) kinetics 449 
for diclofenac and sulfonamide antibiotics in activated sludge (Plósz et al., 2010b, 2012; Falås 450 
et al., 2013) and MBBRs (Falås et al., 2013; Torresi et al., 2016, 2017).  451 
In batch 2, the highest transformation rate constants were observed in S1 for all non-recalcitrant 452 
pharmaceuticals (exhibiting kbio, kdec ≥ 0.1 L gTSS-1 d-1, according to the classification presented 453 
in Joss et al., 2006), with the exception of ATN. An overall decrease of the biotransformation 454 
kinetics in U was shown compared to batch 1. Notably, the order of rate constant values in staged 455 
MBBRs was consistently found to be S1>S2>S3 for all non-recalcitrant compounds, following 456 
the gradient of (i) denitrification rates NOXk observed in the same batch; and (ii) loading and 457 
complexity of available organic substrate during continuous-flow operation. Given that all 458 
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MBBRs had the same specific surface area, the same consideration was valid for surface-459 
normalized biotransformation rate constants (Fig. S10). 460 
In analogy with our study, decreasing influent COD loading was found to negatively influence 461 
the removal efficiency of the estrogen E1 under aerobic conditions (Tan et al., 2013). The 462 
relationship between pharmaceutical transformation and heterotrophic denitrification kinetics 463 
will be discussed more in detail in section 3.3.  464 
< Figure 4 > 465 
Enhanced biotransformation kinetics, as compared to previous findings in DNAS were shown 466 
for SMX, ATN and ERY (Table 2). In particular, kbio values higher than 1.0 L gTSS-1 d-1 were 467 
found in S1, thus indicating a significant increase in biotransformation kinetics for MBBR 468 
biofilm growing under non-limiting COD loading. Comparably high transformation kinetics was 469 
also shown for SMX and ATN in DNMBBR, in the presence of methanol or ethanol was as 470 
electron donor (Torresi et al., 2017). Nevertheless, significant differences in the transformation 471 
kinetics of other substances (e.g., MET, SMZ and TMP) could be observed between pre- and 472 
post-denitrifying conditions. This indicates that the type of electron donor used for NOX 473 
reduction influences not only the activity and the community composition of denitrifiers, but 474 
also their capacity of biotransforming pharmaceuticals (including structural analogues, e.g. ATN 475 
and MET). 476 
Parent-to-retransformable chemical ratios in pre-clarified wastewater (nLI,CJ) were estimated for 477 
SMX, DCF and MET, indicating (particularly for SMX) comparably high concentration levels 478 
of retransformable fractions (CCJ). Values of nLI,CJ for SMX were in agreement with ratios 479 
measured in pre-clarified sewage (Göbel et al., 2007; Plósz et al., 2010b).  480 
Overall, DCF was found to be recalcitrant, in agreement with previous evidences from DNAS 481 
and DNMBBR, but opposed to what observed in NMBBR (Table 2). In batch 2, other 482 
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pharmaceuticals (IBU, IOH, SMZ and VFX) were also found recalcitrant. IBU is known to be 483 
rapidly biodegradable in activated sludge under aerobic conditions (kbio>10 L gTSS-1 d-1; Joss et 484 
al., 2006).While this has been observed also in NMBBRs (Escolá Casas et al., 2015; Torresi et 485 
al., 2016), significant variability in rate constants was shown, whereby also negligible IBU 486 
removal was reported (Falås et al., 2012). Reduced biotransformation was also found in DNAS 487 
(Suarez et al., 2010) and DNMBBR (Torresi et al., 2017) as compared to aerobic conditions, still 488 
significantly higher than in this study. In agreement with our findings, VFX underwent limited 489 
degradation both in NMBBR and DNAS (Falås et al., 2013; Escolá Casas et al., 2015; Torresi et 490 
al., 2016), while enhanced biotransformation via cometabolism was observed in the presence of 491 
methanol or ethanol in DNMBBR (Torresi et al., 2017).   492 
A number of differences were found between the two batch experiments. Values of kbio for TMP 493 
and MET significantly decreased in batch 2, still within the variability of literature rate constants 494 
in DNAS and NMBBR (Table 2). Furthermore, tentative results supporting enantioselective 495 
ATN biotransformation were found in batch 1. Assuming that both ATN enantiomers were 496 
present also during batch 2, this may indicate limited enantioselectivity by MBBR biofilm as a 497 
result of long-term adaptation. Preferential elimination of the S(-)-enantiomer of ATN was 498 
reported in full-activated sludge WWTPs, whereas limited enantioselectivity was shown in 499 
biofilm systems (e.g., trickling filters) (Kasprzyk-Hordern and Baker, 2011). Enantioselective 500 
removal of CIT was also considered to explain EF variations between WWTP influent and 501 
effluent (MacLeod et al., 2007; Evans et al., 2015). Measured EF ratios in WWTP influents were 502 
similar to what estimated in this study for CIT, while differences were shown for ATN (Table 503 
2). 504 
< Table 2 > 505 
 506 
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3.2.3. Removal efficiency during continuous-flow operation 507 
The removal of pharmaceuticals was also investigated during continuous-flow operation of the 508 
single- and three-stage MBBRs, in proximity of batch 1 and 2. Removal efficiencies in the two 509 
systems, calculated from influent and effluent concentrations, are shown in Table S7. Removal 510 
efficiencies in each reactor stage (S1, S2 and S3) were calculated for ATN, CIT, TMP and ERY 511 
(Fig. S14).  512 
Generally, removal efficiencies were in agreement with observations from batch experiments. 513 
ATN and CIT underwent relatively high removal in both single- and three-stage MBRRs (≥ 72% 514 
and 56–67% respectively), as previously observed in post-denitrifying MBBR (HRT=2 h; 515 
Torresi et al., 2017). Intermediate removal efficiencies (25–50%) were shown for TMP and ERY, 516 
also similarly to ethanol- and methanol-dosed post-denitrifying MBBRs, respectively (Torresi 517 
et al., 2017). Formation of SMX and DCF was shown, thus resulting in negative removal 518 
efficiencies (up to -157%) that are in agreement with findings in full-scale WWTPs (Plósz et al., 519 
2010b, 2012; Göbel et al., 2005, 2007). Substances classified as recalcitrant based on estimated 520 
kbio also exhibited limited elimination (removal efficiency <10%).  521 
In the three-stage system, non-recalcitrant and non-retransformable compounds showed highest 522 
removal efficiency in S1 (Fig. S14) with the exception of TMP, which underwent the highest 523 
removal in S3. Interestingly, differences between batch 1 and 2 were reflected by changes in 524 
removal efficiency. SMX and TMP underwent increased (batch 1: -157% and -135%; batch 2: -525 
58% and -39%) and decreased (batch 1: 39% and 49%; batch 2: 24% and 29%) removal 526 
efficiency, respectively, in line with changes in estimated kbio values. 527 
 528 
3.3. Linking denitrification and pharmaceutical biotransformation (batch 2) 529 
Long-term system operation (>450 d) was instrumental in ensuring sufficient biomass adaptation 530 
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(Weiss and Reemtsma, 2008), as exemplified by differences between batch 1 and 2. Prolonged 531 
exposure to increased organic substrate loading and availability in S1 corresponded to an 532 
enhancement of denitrification and biotransformation kinetics. At the same time, biofilm in S1 533 
had access to a broader and more diverse array of carbon sources (including pharmaceuticals), 534 
likely including a higher fraction of readily degradable organic substrates. Hence, on the one 535 
hand, a more active denitrifying community likely populated the biofilm in S1 compared to S3, 536 
of which the latter included a higher fraction of inert biomass (Boltz et al., 2017). This may have 537 
led to a positive influence on the cometabolic biotransformation of a number of pharmaceuticals 538 
(as further discussed in this paragraph) in S1. On the other hand, the exposure to different organic 539 
loading resulted in the development of microbial communities with different degree of 540 
biodiversity in the three-staged MBBR, possibly influencing pharmaceutical biotransformation. 541 
Preliminary results on the influence of reactor staging on microbial community composition in 542 
the MBBRs can be found in Torresi (2017).  543 
Findings in this study are in analogy with observations in a two-stage managed aquifer recharge 544 
system, where carbon availability positively influenced the removal of a number of 545 
pharmaceuticals (as well as denitrifying activity) under anoxic conditions (Hellauer et al., 2017). 546 
Furthermore, increased carbon loading to aerobic activated sludge reactors was beneficial for 547 
the removal of estrone (Tan et al., 2013). On the contrary, staging of aerobic MBBRs resulted 548 
in an overall enhancement of biotransformation kinetics by substrate-limited biofilms in the last 549 
reactor stage (Escolá Casas et al., 2015).  550 
The relationship between denitrification and biotransformation kinetics in S1, S2, S3 and U was 551 
further assessed in detail. Figure 5a and S12a present transformation rate constants for all non-552 
recalcitrant pharmaceuticals, i.e. SMX, ERY, TMP, ATN, and CIT, plotted as a function of NOXk553 
. Strong linear correlations were shown for SMX, ERY and TMP (R2=0.90–0.99; Fig. 5a), while 554 
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weaker correlation was found for ATN and CIT (R2=0.44–0.53; Fig. S13a). Interestingly, 555 
varying regression slopes were shown for the selected pharmaceuticals, possibly indicating 556 
significantly different transformation potential by denitrifying communities (independently of 557 
the available organic substrate). Linear correlations have been previously observed between kbio 558 
and specific nitrification rates for several pharmaceuticals, including trimethoprim (Fernandez-559 
Fontaina et al., 2012). 560 
Similarly, linear correlations were observed between kbio, kdec and µmax (Fig. 5b) and 1-YH (Fig. 561 
5c), although less strong as compared to NOXk  (R2=0.54–0.78). The correlation obtained with 562 
µmax supports reasonably well the positive relationship between kinetics of denitrification and 563 
pharmaceutical biotransformation. The parameter 1-YH denotes the fraction of electron 564 
equivalents used for catabolic respiration (thus, NOX reduction). Accordingly, the utilization of 565 
organic substrate for storage and/or anabolism negatively influenced the removal of 566 
pharmaceuticals, thus further suggesting the association biotransformation with denitrifying 567 
activity. Taken together, these observations point towards the conclusion that biotransformation 568 
of non-recalcitrant pharmaceuticals resulted from cometabolism by denitrifying bacteria. 569 
Simultaneous increased loading and availability of organic substrate, as induced in reactor S1, 570 
can result in a significant enhancement of both heterotrophic denitrification and pharmaceutical 571 
biotransformation capacity as compared to single-stage systems and reactors operated under 572 
substrate-limited conditions.  573 
Considering the positive dependency with heterotrophic denitrification, a cometabolic 574 
biotransformation model was proposed based on the correlations in Fig. 5a (Eq. 10): 575 
LINOXNOXC
LI CkT
dt
dC
,                    (10) 576 
The coefficient TC,NOX (L mgN-1; Eq. 11): 577 
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NOX
decbio
NOXC k
k
T ,,                        (11) 578 
is defined as the transformation coefficient associated to denitrification, and quantifies the 579 
relative pharmaceutical mass (-) transformed per mgN L-1 reduced. TC,NOX was defined in analogy 580 
to coefficients relating kinetics of pharmaceutical transformation and of ammonia oxidation 581 
(Sathyamoorthy et al., 2013). Interestingly, selected pharmaceuticals exhibited a wide range of 582 
TC,NOX values (0.005–0.072 L mgN-1), indicating significantly different transformation potential 583 
by denitrifying communities (independently of the available organic substrate). The presented 584 
model represents one of the first attempts to describe cometabolic biodegradation under pre-585 
denitrifying conditions, and can be used for forward predictions of pharmaceutical removal as a 586 
function of denitrifying activity. Nevertheless, this approach requires further confirmation 587 
through validation with independent datasets. 588 
< Figure 5 > 589 
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4. Conclusions 591 
Based on the experimental (continuous-flow monitoring, batch experiments) and model-based 592 
observations presented in this study, we could draw the following conclusions:  593 
 Reactor staging effectively determined a gradient in organic substrate loading and 594 
availability in the three-stage pre-denitrifying MBBR. Fluctuations in influent composition 595 
led to not negligible dynamics in the denitrification performance during continuous-flow 596 
operation, with an overall decrease of denitrification rates after 400 days of operation.  597 
 Retransformation from conjugated metabolites led to the formation of parent sulfonamide 598 
antibiotics, namely sulfamethoxazole and sulfadiazine. Possible enantioselective 599 
biotransformation was observed for atenolol and citalopram, and a model was developed and 600 
successfully calibrated to describe observed removal kinetics.  601 
 As compared to previous findings for nitrifying MBBR and denitrifying activated sludge, 602 
enhanced biotransformation kinetics were shown for sulfamethoxazole, erythromycin and 603 
atenolol, in particular at higher organic substrate availability. Hence, pre-denitrifying 604 
MBBRs operated under increased organic substrate availability may represent a valid option 605 
to improve the removal of these three pharmaceuticals. 606 
 Tiered organic substrate loading and quality in single-stage and three-stage MBBRs 607 
determined significant differences in the microbial community functions of denitrification 608 
and pharmaceutical biotransformation. After more than 450 days of continuous-flow 609 
operation, the highest denitrification and pharmaceutical biotransformation kinetics were 610 
shown in reactor S1, exposed to the highest electron donor loading and availability.  611 
 When considering all MBBRs, biotransformation rate constants of non-recalcitrant 612 
pharmaceuticals positively correlated with mean specific denitrification rates, maximum 613 
specific growth rates and catabolic electron fractions. This indicates that biotransformation 614 
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of pharmaceuticals is likely a cometabolic process, and that microbial activity both in terms 615 
of primary (denitrification) and secondary (pharmaceutical biotransformation) metabolic 616 
processes activity is more effectively supported by non-limiting organic substrate 617 
availability.  618 
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Tables 811 
Table 1. Summary of model structures identified and used in this study to describe 812 
pharmaceutical concentration profiles observed during batch experiments (batch 1 and 2).  813 
Case Processes 
State variables 
Rate equation 
CLI CEN,1 CEN,2 CCJ 
Biotransformation 
only (Fig. 3a) 
Biotransformation 
of CLI -1    SSLISSd
bio XC
XK
k
1
 
Biotransformation 
and 
retransformation 
(Fig. 3b–c) 
Biotransformation 
of CLI -1    SSLISSd
bio XC
XK
k
1
 
Formation of CLI 
+1 
(+F)* 
 
  -1 SSCJdec XCk  
Enantioselective 
biotransformation 
(Fig. 3d) 
Biotransformation 
of enantiomer 1 (-1) -1   SSEN
SSd
bio XC
XK
k
1,
1,
1
 
Biotransformation 
of enantiomer 2 (-1)  -1  SSENSSd
bio XC
XK
k
2,
2,
1
 
*In case the pharmaceutical has only one known retransformable conjugate (SDZ and AcSDZ), the 
stoichiometry coefficient F should be used, being equivalent to the ratio of the molecular weight of parent 
(MLI) and conjugated (MCJ) pharmaceutical. 
 814 
 Table 2. Summary of kinetic (kbio, kdec, kbio,1, kbio,2 in L gTSS-1 d-1) and stoichiometric (EF—
including the two respective fraction of enantiomer 1 and 2—and  nLI,CJ) parameters estimated 
in this study on pharmaceutical biotransformation and comparison with literature values. 
Chemical Parameter  Batch 1 Batch 2 Literature Ref4 Conditions5 
ATN1,3 
kbio,1 2.7–4.3     
kbio,2 0.0     
EF 0.19 (0.81)  0.30–0.53 A–E RI 
kbio  1.1–2.4 
0.7–0.8 
0.5–5.0 
5.1–6.4 
F  
F, G, H 
I 
DNAS 
NMBBR 
DNMBBR 
CIT3 
kbio,1  2.9–5.1    
kbio,2  0.0–0.4    
kbio   
0.7–3.1 
2.9–4.3 
H 
I 
NMBBR 
DNMBBR 
EF  0.52 (0.48) 0.56–0.60 B, E RI 
ERY1 kbio  0.3–1.0 
0.2 
0.2–0.9 
0.2–0.6 
J 
G, H 
I 
DNAS 
NMBBR 
DNMBBR 
IBU1 kbio  0.00–0.03 
1.5 
0–31 
0.5–1.4 
J 
H, K 
I 
DNAS 
NMBBR 
DNMBBR 
IOH1 kbio  0.00–0.03 
0.0–2.2 
0.3–0.7 
G, H 
I 
NMBBR 
DNMBBR 
SMZ1 kbio  0.02–0.09 
0.2–0.9 
0.0–3.3 
G, H 
I 
NMBBR 
DNMBBR 
TMP1 kbio 0.4–1.0 0.1–0.3 
≤0.1–1.3 
0.1–3.3 
2.1–4.1 
F, L 
F, G, H 
I 
DNAS 
NMBBR 
DNMBBR 
VFX1 kbio  0.02–0.06 
≤0.1 
≤0.1–0.3 
0.1–1.9 
F 
F, G, H 
I 
DNAS 
NMBBR 
DNMBBR 
DCF2 
kbio 0.0 0.00–0.05 
<0.1–1.0 
0.1–5.8 
0.0 
F, J, M 
F, G, H, K 
I 
DNAS 
NMBBR 
DNMBBR 
kdec 3.7–7.4   
5.0 M DNAS 
1.6–2.5 G NMBBR 
nLI,CJ 4.50  0.85 M SI 
MET2 
kbio 0.1–0.3 0.0 
≤0.1 
0.3–1.2 
0.4–0.8 
F 
F, G, H 
I 
DNAS 
NMBBR 
DNMBBR 
kdec 0.5–2.4     
nLI,CJ 3.80     
 SMX2 
kbio 0.7–2.2 1.0–3.5 
0.4 N DNAS 
0.2–1.0 
0.1–3.2 
G, H 
I 
NMBBR 
DMBBR 
kdec 1.9–6.5 0.5–2.1 
1.1–7.9 
0.7–1.6 
F, N 
F 
DNAS 
NMBBR 
nLI,CJ 0.73 0.15 0.13–0.66 N, O SI 
SDZ2 
(Ac-SDZ) 
kbio 0.7–1.7  
0.1–0.7 
0.6–1.0 
G, H 
I 
NMBBR 
DNMBBR 
kdec 1.0–2.0  
<0.1–8.4 
3.7–4.2 
G, H 
I 
NMBBR 
DNMBBR 
 
1Biotransformation only (Eq. 3); 2Bio- and retransformation (Eqs. 4–6); 3Enantioselective biotransformation (Eq. 9–10); 
4References: A=Nikolai et al. (2006); B=MacLeod et al. (2007); C=Kasprzyk-Hordern and Baker (2011); D=Vazquez-Roig et 
al. (2014); E=Evans et al. (2015); F=Falås et al. (2013) (rate constants as L gTAS-1 d-1); G=Torresi et al. (2016) (rate constants 
as L gTAS d-1); H=Escolá-Casas et al. (2015) (rate constants as L gTAS d-1); I=Torresi et al. (2017) (rate constants as L gTAS 
d-1); J=Suarez et al. (2010) (rate constants as L gVSS-1 d-1); K=Falås et al. (2012) (rate constants as L gTAS-1 d-1); L=Su et al. 
(2015) (rate constants as L gCOD-1 d-1); M=Plósz et al. (2012) (rate constants as L gTSS-1 d-1); N=Plósz et al. (2010b) (rate 
constants as L gTSS-1 d-1); O=Göbel et al. (2007); 5Abbreviations: DNAS=Denitrifying Activated Sludge; NMBBR=Nitrifying 
MBBR; DNMBBR=Denitrifying MBBR; RI=Raw Influent; SI=Secondary Influent. 
 
 
  
 Figures 
 
Figure 1. Schematic representation of three-stage (S1, S2, S3) and single-stage (U) MBBR 
systems under continuous-flow operation. The two MBBRs, having overall the same filling ratio 
(33%) and working volume (6 L), were operated in parallel with the same influent flow rate 
(16.2 L d-1) and thus the same hydraulic residence time (HRT=8.9 h). External dosing of 
potassium nitrate (KNO3) was performed to achieve an influent NO3-N concentration of 103 
mgN L-1 in S1 and U reactors. Sparging of N2 gas was used in each MBBR to minimize oxygen 
penetration and ensure carrier mixing in the reactors.  
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Figure 2. Concentration profiles of NOX (a) and total COD (b) measured during anoxic 2 
respirometry (batch 2) in different MBBR reactors. The x-axis in (a) is intentionally subdivided 3 
in two parts of different scales to highlight lag phases in NOX reduction in S2, U and S3. 4 
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Figure 3. Typical profiles of pharmaceutical concentrations observed during batch experiments 7 
(circles) and simulation results with calibrated model (full, dashed and dotted lines): (a) 8 
biotransformation only (ATN, batch 2; Eq. 3); (b, c) retransformation and biotransformation (b: 9 
SMX, batch 1; c: DCF, batch 1; Eq. 5–6); (d) enantioselective biotransformation (ATN, batch 1; 10 
Eq. 9).  11 
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Figure 4. Estimated transformation rate constants for pharmaceuticals in batch 1 (a) and batch 13 
2 (b). The dashed line at kbio = 0.1 L gTSS-1 d-1 (Joss et al., 2006) is used as threshold to identify 14 
recalcitrant and non-recalcitrant pharmaceuticals.  15 
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Figure 5. Estimated transformation rate constants (kbio, kdec) for non-recalcitrant pharmaceuticals plotted as a function of (a) mean 18 
specific denitrification rate ( NOXk ), (b) maximum specific growth rate (µmax) and (c) catabolic electron fraction (1-YH) during batch 2 19 
in different MBBR reactors (S1, S2, S3, U). Linear regressions (solid lines) are used to indicate the possible correlation between 20 
denitrification and pharmaceutical removal kinetics for each substance (numbers in the figure denote the R2 values of each regression).  21 
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